Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Outcomes for patients with chronic lymphocytic leukemia (CLL) diagnosed at a young age (≤40 years) are not well-characterized.
• Understanding differences in disease presentation and progression between young and older CLL patients is crucial for personalized treatment strategies.

Purpose of the Study:

• To compare the clinical characteristics, treatment patterns, and survival outcomes of very young CLL patients (≤40) with older patients (>40).
• To identify factors influencing treatment initiation and prognosis in different age groups.

Main Methods:

• Retrospective comparison of 71 very young CLL patients with 142 age-matched older patients from an institutional cohort.
• Utilized the Surveillance, Epidemiology, and End Results (SEER) database for independent validation.
• Compared baseline characteristics, including Rai stage, cytogenetics, IGHV mutation status, ZAP70 expression, beta-2-microglobulin levels, and incidence of second malignancies.

Main Results:

• Very young and older patients presented with similar Rai stage, adverse cytogenetics, IGHV mutation, and ZAP70 expression rates.
• Younger patients had lower beta-2-microglobulin levels and fewer second malignancies at diagnosis.
• No significant differences were observed in autoimmune manifestations, family history, time to therapy, response to treatment, or Richter's transformation.
• Unmutated IGHV and elevated lactate dehydrogenase (LDH) were associated with shorter time to treatment initiation in both groups.
• A trend towards longer 5-year survival was observed in very young patients (93% vs. 82%), validated by SEER data.

Conclusions:

• Very young patients with CLL exhibit similar disease characteristics and response to therapy as older patients, with a potential survival advantage.
• Factors such as unmutated IGHV and elevated LDH are critical predictors for treatment initiation across age groups.
• Further research is warranted to elucidate the long-term implications of early-onset CLL.